Other psychostimulants and nootropics
ATC code: N06BX03 (Piracetam)
A cyclic GABA derivative. The exact mechanism is not fully established. Manufacturer claims and early publications suggest modulation of AMPA receptors, effects on neuronal membrane fluidity, and improved interhemispheric transfer. At the level of clinical outcomes in people without neurodegenerative disease, these effects have not been reproduced in independent studies.
Not recommended
A 2001 Cochrane Review of piracetam in dementia and cognitive impairment reported a weak positive effect with high risk of bias and methodological problems. No independent update has been published since. International dementia guidelines (NICE NG97, AAN 2018) do not include piracetam. The drug is not registered as a medicine in the United States; FDA issued warnings to supplement manufacturers using piracetam in 2004 and 2010.
Not recommended
International ADHD guidelines (AAP 2019, NICE NG87) list psychostimulants (methylphenidate, lisdexamfetamine), atomoxetine, and behavioural therapy as first-line. Piracetam is not in these documents. Russian paediatric practice sometimes prescribes it 'to improve concentration' – this contradicts the guidelines.
Not recommended
Piracetam is promoted in biohacker communities as the 'original nootropic' for cognitive enhancement in healthy adults. In RCTs in healthy adults, piracetam has not shown clinically meaningful improvement in memory, concentration, or mental speed. FDA issued warnings in 2004 and 2010 to supplement manufacturers using unregistered piracetam.
Not recommended
Piracetam is not included in international stroke rehabilitation guidelines (AHA/ASA 2023, ESO 2022). Recovery relies on early mobilisation, physical, occupational, and speech therapy, and cardiovascular risk management.
Not recommended
For subjective memory complaints without objective cognitive impairment, international sources recommend cognitive training, treatment of reversible causes (depression, sleep apnoea, B12 deficiency, hypothyroidism), and vascular risk management. Nootropics are not prescribed for this scenario.
Contraindicated in pregnancy.
Contraindicated during breastfeeding.
Piracetam is evaluated for the following indications with varying evidence strength: Cognitive impairment (evidence tier D), Post-stroke recovery (evidence tier F), Cognitive enhancement in healthy adults (marketed indication) (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Piracetam (≥ 1 in 100): Nervousness, agitation, Insomnia, Nausea, diarrhoea, Weight gain. See the Safety section for uncommon and serious reactions.
Contraindicated in pregnancy.
Contraindicated during breastfeeding.
Piracetam is contraindicated in: Hypersensitivity to pyrrolidone derivatives; Severe renal failure (CrCl < 20 mL/min); Haemorrhagic stroke; Huntington's disease; Pregnancy and breastfeeding. Full list in the Safety section.
systematic reviews of cognitive enhancement in healthy people (Cochrane, international neuroethics working groups) show effects that are absent or very small, with unassessed long-term risks. Sleep, physical activity, learning, and engagement are what genuinely improve cognition.